These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 12734030)
1. Identifying the osteopenic patient and preventing worsening of the disease. Derman R Curr Womens Health Rep; 2003 Jun; 3(3):199-206. PubMed ID: 12734030 [TBL] [Abstract][Full Text] [Related]
2. Aging bone and osteoporosis: strategies for preventing fractures in the elderly. Ettinger MP Arch Intern Med; 2003 Oct; 163(18):2237-46. PubMed ID: 14557222 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis. Iwamoto J; Takeda T; Sato Y Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313 [TBL] [Abstract][Full Text] [Related]
4. Therapeutic options: an evidence-based approach to prevention and treatment of osteoporosis. Miller E Int J Fertil Womens Med; 2003; 48(3):122-6; discussion 137-8. PubMed ID: 12839143 [TBL] [Abstract][Full Text] [Related]
6. Drugs for prevention and treatment of postmenopausal osteoporosis. Med Lett Drugs Ther; 2000 Oct; 42(1090):97-100. PubMed ID: 11035622 [No Abstract] [Full Text] [Related]
8. Health-economic comparison of three recommended drugs for the treatment of osteoporosis. Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171 [TBL] [Abstract][Full Text] [Related]
9. Antiresorption therapy and reduction in fracture susceptibility in the osteoporotic elderly patient: open study. Muscoso E; Puglisi N; Mamazza C; Lo Giudice F; Testai M; Abbate S; Santangelo A; Panebianco P; Maugeri D Eur Rev Med Pharmacol Sci; 2004; 8(2):97-102. PubMed ID: 15267123 [TBL] [Abstract][Full Text] [Related]
10. Alendronate in the treatment of osteoporosis. Adami S Aging (Milano); 1998 Apr; 10(2):159-60. PubMed ID: 9666215 [No Abstract] [Full Text] [Related]
11. Alendronate in combination with calcium and vitamin D prevents bone loss after orthotopic liver transplantation: a prospective single-center study. Millonig G; Graziadei IW; Eichler D; Pfeiffer KP; Finkenstedt G; Muehllechner P; Koenigsrainer A; Margreiter R; Vogel W Liver Transpl; 2005 Aug; 11(8):960-6. PubMed ID: 16035083 [TBL] [Abstract][Full Text] [Related]
12. Prevalence of evaluation and treatment of glucocorticoid-induced osteoporosis in men. Cruse LM; Valeriano J; Vasey FB; Carter JD J Clin Rheumatol; 2006 Oct; 12(5):221-5. PubMed ID: 17023807 [TBL] [Abstract][Full Text] [Related]
13. [Osteoporosis treatment: the point of view of the gynecologist]. Lopes P Contracept Fertil Sex; 1998 Jun; 26(6):408-11. PubMed ID: 9691516 [No Abstract] [Full Text] [Related]
14. [Risk of osteoporosis in postmenopausal women. When is bone density measurement indicated?]. MMW Fortschr Med; 2004 May; 146(21):63. PubMed ID: 15373093 [No Abstract] [Full Text] [Related]
15. Effect of risedronate on biochemical marker of bone resorption in postmenopausal women with osteoporosis or osteopenia. Dane C; Dane B; Cetin A; Erginbas M Gynecol Endocrinol; 2008 Apr; 24(4):207-13. PubMed ID: 18382907 [TBL] [Abstract][Full Text] [Related]
16. Etidronate and hormone replacement therapy (HRT) for postmenopausal women with osteoporosis despite HRT. Morishige K; Yamamoto T; Sawada K; Ohmichi M; Tasaka K; Murata Y Arch Gynecol Obstet; 2003 Jun; 268(2):105-6. PubMed ID: 12768299 [TBL] [Abstract][Full Text] [Related]
17. Bone mineral density among postmenopausal Saudi women. Sadat-Ali M; Al-Habdan IM; Al-Mulhim FA; El-Hassan AY Saudi Med J; 2004 Nov; 25(11):1623-5. PubMed ID: 15573189 [TBL] [Abstract][Full Text] [Related]
18. Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis. Guañabens N; Parés A; Ros I; Alvarez L; Pons F; Caballería L; Monegal A; Martínez de Osaba MJ; Roca M; Peris P; Rodés J Am J Gastroenterol; 2003 Oct; 98(10):2268-74. PubMed ID: 14572578 [TBL] [Abstract][Full Text] [Related]
19. American Association of Clinical Endocrinologists 2001 Medical Guidelines for Clinical Practice for the Prevention and Management of Postmenopausal Osteoporosis. American Association of Clinical Endocrinologists Osteoporosis Task Force Endocr Pract; 2001; 7(4):293-312. PubMed ID: 11508261 [No Abstract] [Full Text] [Related]
20. Statins have additive effects to vertebral bone mineral density in combination with risedronate in hypercholesterolemic postmenopausal women. Tanriverdi HA; Barut A; Sarikaya S Eur J Obstet Gynecol Reprod Biol; 2005 May; 120(1):63-8. PubMed ID: 15866088 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]